SCHEMBL8559792

SCHEMBL8559792

Nc1ccc(S(=O)(=O)c2ccc3ccccc3n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 3/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ CYP3A4 P08684 3/20 0.48
▸ LMNA P02545 3/20 0.48
▸ CYP2C9 P11712 3/20 0.48
▸ MPO P05164 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ MAPT P10636 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ PKM P14618 2/20 0.47
▸ GMNN O75496 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ THPO P40225 1/20 0.47
▸ BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5670238 0.86 HDAC1 (0.53) HTR6KMT2ALMNAALDH1A1KDM4E
SCHEMBL30483849 0.86 HDAC1 (0.53) HTR6KMT2ALMNAALDH1A1KDM4E
SCHEMBL28440582 0.83 KDM4E (0.57) KMT2ARAB9ALMNAALDH1A1KDM4E
SCHEMBL31315377 0.83 AKR1B1 (0.47) MEN1KMT2ANPC1LMNAKDM4E
SCHEMBL28271752 0.83 HTT (0.65) MEN1KMT2ANPC1RAB9ACYP3A4
SCHEMBL8566588 0.80 HDAC1 (0.46) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL28270267 0.80 KDM4E (0.60) MEN1KMT2ARAB9ALMNAALDH1A1
SCHEMBL8561198 0.80 AGTR1 (0.56) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL28270265 0.80 PKM (0.68) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL28897459 0.80 AKR1B1 (0.51) LMNAALDH1A1MAPTSMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5814646-A TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS ELI LILLY AND COMPANY (US) 1998-09-29 — — US disclosed
US-5624937-A TREATMENT OF ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1997-04-29 — — US disclosed
Send feedback